文献速递泌尿生殖与妇科肿瘤放疗

局限性前列腺癌根治性放疗联合雄激素剥夺治疗后的决策后悔与困扰

Decision Regret and Bother With the Addition of Androgen Deprivation Therapy to Definitive Radiation Treatment for Localized Prostate Cancer.
PubMed 文献 · Pract Radiat Oncol · 2023-05-10

本研究纳入846例接受根治性放疗的前列腺癌患者,其中356例接受了雄激素剥夺治疗(ADT),234例(66%)完成问卷。54%的患者因ADT感到一定困扰,最常见为潮热(32%)、乏力(29%)和性功能问题(29%);5%的患者对接受ADT表示「相当」或「非常」后悔。约三分之一患者认为1%的总生存(OS)获益即值得ADT,而34%需要>10%的OS获益才愿再次选择ADT;接受短期ADT者中49%愿为6%的OS获益接受更长疗程。

要点

  • 54%的患者因ADT感到一定困扰,最常见为潮热(32%)、乏力(29%)和性功能问题(29%)。
  • 5%的患者对接受ADT表示「相当」或「非常」后悔。
  • 约三分之一认为1% OS获益即值得ADT,34%需>10% OS获益才愿再次选择;短期ADT者中49%愿为6% OS获益接受更长疗程。

核心结论

  • 对ADT的显著后悔率较低(5%)。
  • 患者对ADT所需OS获益的阈值呈现明显二分:部分认为任何OS获益均值得,部分则需显著生存获益才愿承受副作用。
  • 鉴于部分患者可能在经历ADT副作用后改变对ADT相对价值的看法,本研究强调在6个月后对患者进行复诊,以提供重新协商治疗的机会。

研究设计与样本

  • 研究纳入846例接受根治性放疗的前列腺癌患者,其中356例接受了ADT并询问其ADT体验。
  • 234例(66%)患者完成问卷,使用4点量表评估ADT副作用及困扰程度,并询问后悔程度及可接受ADT的生存获益阈值。

主要发现

  • 54%的患者因ADT感到一定困扰,最常见为潮热(32%)、乏力(29%)和性功能问题(29%)。
  • 5%的患者对接受ADT表示「相当」或「非常」后悔。
  • 约三分之一患者认为1%的OS获益即值得ADT,而34%需要>10%的OS获益才足以再次选择ADT。
  • 接受短期ADT的患者中,49%愿为6%的OS获益接受更长疗程的ADT。

临床怎么用

  • 作者强调在患者经历ADT副作用后,于6个月后复诊并重新协商治疗,以尊重患者对ADT相对价值的可能变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Androgen deprivation therapy (ADT) combined with radiation treatment (RT) is recommended by the National Comprehensive Cancer Network guidelines for unfavorable intermediate and high-risk localized prostate cancer. Although there is a variable survival benefit conferred by ADT, there are potential side effects to consider for patient decision-making. We aimed to assess the side effects and bother of adding ADT to RT, the degree of regret, and what overall survival (OS) benefit men would want to justify adding or extending the duration of ADT, after their experience with this treatment. METHODS AND MATERIALS: Men receiving ADT with definitive RT completed a questionnaire asking about the side effects and degree of bother from ADT using a 4-point scale. They were also asked about regret, and what survival benefit would warrant ADT. RESULTS: In the study, 846 patients received definitive RT, of whom 356 received ADT and were asked about their experience with ADT. Of these, 234 responded (66%). In 54%, ADT caused some bother, most commonly hot flushes (32%), fatigue (29%), and sexual problems (29%). Five percent regretted receiving ADT "quite a lot" or "very much." Approximately one-third of men deemed a 1% OS benefit from ADT worthwhile, whereas one-third (34%) would want a >10% OS benefit enough to justify choosing ADT again. In addition, 49% of patients who received short-term ADT would accept longer duration ADT for a 6% OS benefit. CONCLUSIONS: Significant regret for ADT was low (5%). There was a clear dichotomy between those who deemed any OS benefit from ADT worthwhile versus those who needed a significant survival benefit to justify the side effects. Given that some men may change their opinion on the relative value of ADT after experiencing its effects, this study emphasizes the importance of revisiting patients after 6 months to given patients an opportunity to renegotiate their treatment.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Booth V, Eade T, Hruby G, et al. Decision Regret and Bother With the Addition of Androgen Deprivation Therapy to Definitive Radiation Treatment for Localized Prostate Cancer. Pract Radiat Oncol. 2023. PMID: 37169149. doi:10.1016/j.prro.2023.04.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。